Intellectual Property Magazine

Maura O'Malley

Document

UK High Court invalidates ‘insufficient’ FibroGen patents

Ben Wodecki

Akebia and Otsuka have successfully defeated six anaemia-related patents owned by FibroGen, after the UK High Court found five to be invalid and one would not be infringed should the pair bring their rival product, vadadustat, to market.

The rest of this document is only available to i-law.com online subscribers.

If you are already a subscriber, click Log In button.